

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number
WO 2022/034130 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 15/86 (2006.01)
A61K 38/00 (2006.01) C12N 15/67 (2006.01)
A61P 25/28 (2006.01) C12N 15/79 (2006.01)
C07K 14/47 (2006.01)

TEL, Toshal, Rohit; UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE). **DOWNEY, Patrick, Mark**; UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE). **SHRIVASTAVA, Amulya, Nidhi**; UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE).

(21) International Application Number:

PCT/EP2021/072365

(74) **Agent: J A KEMP LLP**; 80 Turnmill Street, London EC1M 5QU (GB).

(22) International Filing Date:

11 August 2021 (11.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/064,431 12 August 2020 (12.08.2020) US

(71) **Applicant: UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE).


(72) **Inventors: DALAL, Nikita**; c/o Element Genomics, 701 W Main St. Ste 200, Durham, North Carolina 27701 (US). **KABADI, Ami**; c/o Element Genomics, 701 W Main St. Ste 200, Durham, North Carolina 27701 (US). **PA-**

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) **Title:** GENE THERAPY USING NUCLEIC ACID CONSTRUCTS COMPRISING METHYL CPG BINDING PROTEIN 2 (MECP2) PROMOTER SEQUENCES

FIGURE 1



(57) **Abstract:** The present invention relates to nucleic acid constructs comprising methyl CpG binding protein 2 (MeCP2) promoter sequences. The present invention further relates to vectors, viral vectors host cells and pharmaceutical compositions comprising said nucleic acid constructs. The present invention also concerns the therapeutic use of said nucleic acid constructs, vectors, viral vectors and pharmaceutical compositions.

[Continued on next page]



WO 2022/034130 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*